Novel Angiogenesis Inhibitors in NSCLC

For High-Definition, Click

Promising findings for angiogenesis inhibitors in non-small cell lung cancer (NSCLC) were presented at the 2014 ASCO Annual Meeting. In the phase III SQUIRE trial, adding necitumumab to gemcitabine and cisplatin improved overall survival (OS) by 1.6 months over the chemotherapy alone. In a second trial, labeled REVEL, ramucirumab plus docetaxel improved OS by 1.4 months compared with docetaxel alone. Additionally, in earlier reported studies, treatment with nintedanib plus docetaxel improved OS by 2.3 months versus chemotherapy alone for patients with NSCLC.

These studies offer a glimpse of benefit with these agents; however, more research is needed to optimize their administration. At this time, more research is needed to identify a biomarker for angiogenesis inhibitors in NSCLC, and other types of cancer.

In this discussion, panelists explore angiogenesis inhibition and biomarker discovery in NSCLC in depth. View the video, to learn more!